Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $431M (up 50.1% year over year) with net income of $55M.
Q3 2026 key financials · XBRL
- Revenue
- $431M
- +50.1% YoY · +18.4% QoQ
- Net income
- $55M
- +148.6% YoY · +195.7% QoQ
- Operating margin
- 13.0%
- EPS (diluted)
- $1.92
- +137.6% YoY · +196.5% QoQ
Source: XBRL data from the MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q3 2026 10-Q on SEC EDGAR. USD.
MADRIGAL PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $431.3M, up $144.0M YoY, driven by increased U.S. Rezdiffra demand
- Operating margin 13.0% vs negative 39.7% YoY, with operating income $56.0M vs loss of $114.0M
- Rezdiffra, sole reported product, generated $431.3M revenue and $37.8M cost of sales
- Cash, restricted cash and marketable securities $961.8M vs $988.6M at December 31, 2025
- Operating cash use $23.6M year-to-date, with $320.2M investing inflow and $15.4M financing inflow
Risk Factors
- Newly highlighted clinical-trial risk: FDA, EMA conditions, enrollment delays, supply shortages, or adverse effects could postpone approvals and commercialization
- Most materially updated financial risk: $2,187.4 million accumulated deficit despite $55.4 million quarterly net income
- Regulatory risk: FDA-required Rezdiffra post-marketing commitments and clinical trials could increase costs or delay commercialization
- Operational risk: Delayed trial completion could allow competitors to commercialize products first
- Liquidity risk: $961.8 million in cash, restricted cash, and marketable securities as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MADRIGAL PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.